Vivos Therapeutics Receives Groundbreaking FDA 510 ( k ) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring - Vivos Therapeutics ( NASDAQ:VVOS )

2 months ago

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea ( OSA ) market with new FDA clearance and new strategic marketing and distribution model Vivos' DNA appliance now approved to reduce snoring and treat moderate to severe OSA in children aged 6 to 17

Ticker	Sentiment	Impact
VVOS	Neutral	10 %